1. Dual Effects of Chinese Herbal Medicines on Angiogenesis in Cancer and Ischemic Stroke Treatments: Role of HIF-1 Network
   Ming Hong et al, 2019, Front. Pharmacol. CrossRef
2. Rhaponticin as an anti-inflammatory component of rhubarb: a minireview of the current state of the art and prospects for future research
   Joanna Kolodziejczyk-Czepas et al, 2019, Phytochem Rev CrossRef
3. Metabolism of Rhaponticin and Activities of its Metabolite, Rhapontigenin: A Review
   Dan Chen et al, 2020, CMC CrossRef
4. Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity
   Jianbo He et al, 2021, Front. Pharmacol. CrossRef
5. Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
   Eugenia D. Teodor et al, 2021, CBC CrossRef
6. Mechanism Analysis of Antiangiogenic d-Isofloridoside from Marine Edible Red algae Laurencia undulata in HUVEC and HT1080 cell
   Shengtao Yang et al, 2021, J. Agric. Food Chem. CrossRef
7. Microvascular Experimentation in the Chick Chorioallantoic Membrane as a Model for Screening Angiogenic Agents including from Gene-Modified Cells
   Donna C. Kennedy et al, 2021, IJMS CrossRef
8. Arsenic Trioxide Restrains Lung Cancer Growth and Metastasis by Blocking the Calcineurin-NFAT Pathway by Upregulating DSCR1
   Meng-Hang Yang et al, 2022, CCDT CrossRef
9. Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review
   Shuang Luo et al, 2022, Front. Pharmacol. CrossRef
10. Extracellular Matrix Remodeling Enzymes as Targets for Natural Antiangiogenic Compounds
    Paloma Carrillo et al, 2023 CrossRef
11. Anticancer Activity of Endemic Phlomis Extracts in HCT116 Human Colon Cancer Cells
    Yener KURMAN et al, 2023, SABD CrossRef
12. Identification of PIMREG as a novel prognostic signature in breast cancer via integrated bioinformatics analysis and experimental validation
    Wenjing Zhao et al, 2023 CrossRef
13. Rhaponticin suppresses the stemness phenotype of gastric cancer stem-like cells CD133+/CD166 + by inhibiting programmed death-ligand 1
    Yulong Li et al, 2024, BMC Gastroenterol CrossRef